After a busy few weeks of news about Merck ‘s cancer-drug pipeline, the pharmaceutical company will announce its quarterly financial results on Thursday.
Wall Street analysts expect Merck to report earnings of $1.95 per share for the third quarter, up from $1.85 in the same quarter last year, according to FactSet. They expect sales of $15.3 billion, compared with $15 billion a year earlier. Also last week, Merck disclosed positive data from a number of trials, many involving Keytruda, its megablockbuster cancer immunotherapy. One Merck presentation, saying overall survival was increased by half in patients with urothelial cancer who received Keytruda in combination with the Seagen and Astellas Pharma drug Padcev, “earned a standing ovation,” according to a note from Goldman Sachs analyst Chris Shibutani.
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
Trading Earnings Season: 3 Steps for Using Earnings ReportsLearn how to trade earnings season, with tips on choosing companies and researching market conditions to establishing a strategy.
Sumber: DailyFX - 🏆 305. / 63 Baca lebih lajut »
Sumber: WSJ - 🏆 98. / 63 Baca lebih lajut »
Sumber: MarketWatch - 🏆 3. / 97 Baca lebih lajut »
Sumber: Investingcom - 🏆 450. / 53 Baca lebih lajut »
Sumber: MarketWatch - 🏆 3. / 97 Baca lebih lajut »
Sumber: MarketWatch - 🏆 3. / 97 Baca lebih lajut »